588 related articles for article (PubMed ID: 35286905)
1. Factors influencing clinician prescribing of disease-modifying anti-rheumatic drugs for inflammatory arthritis: A systematic review and thematic synthesis of qualitative studies.
Lalor AF; Brooker JE; Rozbroj T; Whittle SL; Hill CL; Rowett D; Buchbinder R; O'Connor DA
Semin Arthritis Rheum; 2022 Aug; 55():151988. PubMed ID: 35286905
[TBL] [Abstract][Full Text] [Related]
2. Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data.
Steffen A; Holstiege J; Klimke K; Akmatov MK; Bätzing J
Rheumatol Int; 2018 Nov; 38(11):2111-2120. PubMed ID: 30306254
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity.
Prawjaeng J; Leelahavarong P; Budtarad N; Pilasant S; Chanjam C; Katchamart W; Narongroeknawin P; Kitumnuaypong T
BMC Health Serv Res; 2023 May; 23(1):561. PubMed ID: 37259090
[TBL] [Abstract][Full Text] [Related]
4. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
[TBL] [Abstract][Full Text] [Related]
5. Patients' Attitudes and Experiences of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis.
Kelly A; Tymms K; Tunnicliffe DJ; Sumpton D; Perera C; Fallon K; Craig JC; Abhayaratna W; Tong A
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):525-532. PubMed ID: 28732151
[TBL] [Abstract][Full Text] [Related]
6. Effects of biologic and target synthetic disease-modifying anti-rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta-analysis.
Ben Tekaya A; Mehmli T; Ben Sassi M; Teyeb Z; Bouden S; Rouached L; Mahmoud I; Dziri C; Abdelmoula L
Clin Rheumatol; 2023 Apr; 42(4):979-997. PubMed ID: 36462127
[TBL] [Abstract][Full Text] [Related]
7. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage.
Tatangelo M; Tomlinson G; Paterson JM; Ahluwalia V; Kopp A; Gomes T; Bansback N; Bombardier C
JAMA Netw Open; 2019 Dec; 2(12):e1917053. PubMed ID: 31808927
[TBL] [Abstract][Full Text] [Related]
8. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.
Woodworth TG; den Broeder AA
Best Pract Res Clin Rheumatol; 2015; 29(4-5):543-9. PubMed ID: 26697765
[TBL] [Abstract][Full Text] [Related]
9. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Smolen JS; Landewé R; Bijlsma J; Burmester G; Chatzidionysiou K; Dougados M; Nam J; Ramiro S; Voshaar M; van Vollenhoven R; Aletaha D; Aringer M; Boers M; Buckley CD; Buttgereit F; Bykerk V; Cardiel M; Combe B; Cutolo M; van Eijk-Hustings Y; Emery P; Finckh A; Gabay C; Gomez-Reino J; Gossec L; Gottenberg JE; Hazes JMW; Huizinga T; Jani M; Karateev D; Kouloumas M; Kvien T; Li Z; Mariette X; McInnes I; Mysler E; Nash P; Pavelka K; Poór G; Richez C; van Riel P; Rubbert-Roth A; Saag K; da Silva J; Stamm T; Takeuchi T; Westhovens R; de Wit M; van der Heijde D
Ann Rheum Dis; 2017 Jun; 76(6):960-977. PubMed ID: 28264816
[TBL] [Abstract][Full Text] [Related]
10. Promoting and supporting self-management for adults living in the community with physical chronic illness: A systematic review of the effectiveness and meaningfulness of the patient-practitioner encounter.
Rees S; Williams A
JBI Libr Syst Rev; 2009; 7(13):492-582. PubMed ID: 27819974
[TBL] [Abstract][Full Text] [Related]
11. Patient and rheumatologist perspectives on tapering DMARDs in rheumatoid arthritis: a qualitative study.
Hazlewood GS; Loyola-Sanchez A; Bykerk V; Hull PM; Marshall D; Pham T; Barber CEH; Barnabe C; Sirois A; Pope J; Schieir O; Richards D; Proulx L; Bartlett SJ
Rheumatology (Oxford); 2022 Feb; 61(2):606-616. PubMed ID: 33878168
[TBL] [Abstract][Full Text] [Related]
12. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
[TBL] [Abstract][Full Text] [Related]
13. Healthcare professionals' perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis.
Voshaar MJH; van den Bemt BJF; van de Laar MAFJ; van Dulmen AM; Vriezekolk JE
BMC Health Serv Res; 2022 Jan; 22(1):62. PubMed ID: 35022034
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing the prescription of intensive combination treatment strategies for early rheumatoid arthritis.
Meyfroidt S; van Hulst L; De Cock D; Van der Elst K; Joly J; Westhovens R; Hulscher M; Verschueren P
Scand J Rheumatol; 2014; 43(4):265-72. PubMed ID: 24559216
[TBL] [Abstract][Full Text] [Related]
15. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Chiu YM; Chen DY
Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
[No Abstract] [Full Text] [Related]
16. Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database.
Hepworth E; Movahedi M; Rampakakis E; Mirza R; Lau A; Cesta A; Pope J; Sampalis JS; Bombardier C
Curr Rheumatol Rev; 2021; 17(3):349-359. PubMed ID: 33308132
[TBL] [Abstract][Full Text] [Related]
17. Rheumatoid arthritis: previously untreated early disease.
Gunasekera WM; Kirwan JR
BMJ Clin Evid; 2016 Aug; 2016():. PubMed ID: 27479367
[TBL] [Abstract][Full Text] [Related]
18. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.
Heather EM; Payne K; Harrison M; Symmons DP
Pharmacoeconomics; 2014 Feb; 32(2):109-34. PubMed ID: 24338344
[TBL] [Abstract][Full Text] [Related]
19. A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy.
Wong PKK; Bagga H; Barrett C; Chong G; Hanrahan P; Kodali T; Marabani M; Prince HM; Riordan J; Swarbrick P; White R; Young L
Curr Rheumatol Rep; 2018 Sep; 20(10):64. PubMed ID: 30173305
[TBL] [Abstract][Full Text] [Related]
20. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
